a public good project by the
Synthesis
Company
of California

© 2026

F. Stephen Hodi | doi.page

0 works0 citations0 h-index

F. Stephen Hodi

Harvard University(US)Massachusetts General Hospital(US)Dana-Farber Cancer Institute(US)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management

Most-Cited Works

→ Improved Survival with Ipilimumab in Patients with Metastatic Melanoma(2010)15,035 cited
→ Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer(2012)12,527 cited
→ Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
→ Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
→ Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients(2014)5,215 cited
→ Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited

→ Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)

3,383 cited

→ Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria(2009)3,202 cited

→ Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma(2015)2,746 cited

→ Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial(2015)2,648 cited